Castle BiosciencesvsJohnson & Johnson

CSTL and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CSTL

Castle Biosciences, Inc.

$33.38

Value $992M

+1.21%
CSTL's page

Castle Biosciences (CSTL) has a market value of $992M and Johnson & Johnson (JNJ) $657B. Over the last year, with dividends, CSTL moved -1.7% and JNJ +39.7%. Dividend yield: CSTL none, JNJ 1.94%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CSTL$992M

    JNJ$657B

    JNJ is 662 times CSTL

  • Revenue, 12 months

    CSTL$377M

    JNJ$99.3B

    JNJ is 263 times CSTL

  • Net income, 12 months

    CSTL-$23M

    JNJ$16.1B

  • Operating margin

    CSTL-7.4%

    JNJ–

  • ROIC

    CSTL-4.6%

    JNJ12.4%

    17.0 points apart

  • P/E

    CSTL–

    JNJ40.8

  • Dividend yield

    CSTL0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    CSTL-36.3%

    JNJ+92.0%

    128.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CSTL-36.3%

JNJ+92.0%

5010015020020222023202420252026
Returns by period
PeriodCSTLWith dividendsJNJWith dividends
1 year since November 17, 2025-1.7%Price -1.7%+39.7%Price +36.6%
3 years since November 17, 2023+70.0%+19.3% a yearPrice +70.0%+98.2%+25.6% a yearPrice +82.1%
5 years since November 17, 2021-36.3%-8.6% a yearPrice -36.3%+92.0%+13.9% a yearPrice +67.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CSTLCastle BiosciencesJNJJohnson & Johnson

Valuation

CSTLJNJ
Valuation
Price$33.38$272.70
Market value$992M$657B
Enterprise value (EV)$725M$685B
P/E–40.8
P/E, 5-year median–21.9
P/B2.18.1
EV/EBIT–38.6
Free cash flow yield0.4%3.1%

Results and growth

CSTLJNJ
Results and growth
Revenue, 12 months$377M$99.3B
Net income, 12 months-$23M$16.1B
Free cash flow, 12 months$4.0M$20.6B
Earnings per share, 12 months-$0.76$6.59
Revenue growth, year on year3.7%6.1%
Revenue growth a year, past+40.6%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CSTLJNJ
Margins and returns on capital
Gross margin77.1%67.6%
Operating margin-7.4%–
Net margin-6.1%16.2%
ROIC-4.6%12.4%
ROE-4.9%19.7%

Balance sheet

CSTLJNJ
Balance sheet
Cash$278M$17.2B
Total debt$37M$44.7B
Net debt / EBITDA-21.01.1
Interest cover-51.2×18.0×

Dividends and buybacks

CSTLJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CSTL or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Castle Biosciences or Johnson & Johnson?

By market value, Johnson & Johnson ($657B) is about 662.2 times Castle Biosciences ($992M), at today's prices.

How did CSTL and JNJ stock do over the last 5 years?

Since November 17, 2021, CSTL's price moved -36.3% and JNJ's +67.0%. With dividends: CSTL -36.3% (-8.6% a year), JNJ +92.0% (+13.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, CSTL or JNJ?

The dividend yield at today's price is none for Castle Biosciences and 1.94% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Castle Biosciences or Johnson & Johnson?

Over the last twelve months, the net margin was -6.1% for Castle Biosciences and 16.2% for Johnson & Johnson, and the operating margin -7.4% and –. Revenue was $377M and $99.3B.

Which is the better investment, Castle Biosciences or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.